Genmab — December 2012
-
og kommer direkte fra deres posters
-
in vitro og in vivo er ofa bedre end rituxian i MCL
-
der er lavet noget sekventiel dosering mellem ofa og lenalidomide
-
i cll refrac
-
det så lovende ud
-
så er der senior ofa
-
hvorman skal være pensionist for at få det
-
så er der sammenligning med ritux
-
orr 86% målt efter 1996 kriterierne
-
det er lidt kritisk og kompliceret at referere
-
mere head to head ritux agtigt forsøg
-
ofa beater ritux
-
24% vs 12%
-
i cr
-
Konklusion
-
Ofa er superior over RTX i preklinikken
-
O-Chop 100% ORR
-
selv med 67% flipi score
-
så OFA kan i flere indikationer
-
very encouraging data
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind